Cytek Biosciences, Inc. CTKB Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s operating lease right-of-use asset amortization?
- Cytek Biosciences, Inc. (CTKB) reported operating lease right-of-use asset amortization of $948K in Q1 2026.
- How has Cytek Biosciences, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Cytek Biosciences, Inc.'s operating lease right-of-use asset amortization decreased by 6.0% year-over-year, from $1.01M to $948K.
- What is the long-term trend for Cytek Biosciences, Inc.'s operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), Cytek Biosciences, Inc.'s operating lease right-of-use asset amortization has grown at a 11.6% compound annual growth rate (CAGR), from $3.17M to $4.4M.